NOTRELOAD AI
  • NOTRELOAD AI
  • Invest ↗
  • myNOTRELOAD (BETA)
  • XY Feed
  • 24-HOUR Pass →
Sign in Subscribe

Elastic Raises Full-Year Guidance After Strong Q1 and Record Large-Customer Growth

Elastic beat Q1 estimates, raised full-year guidance, and reported record large-customer growth as AI workloads expanded across its platform.

Elastic Raises Full-Year Guidance After Strong Q1 and Record Large-Customer Growth
Credit: Michael Nagle/Bloomberg
Already have an account? Sign in.
08/28/2026 · 6:31 AM
ESTC
/ Don’t stop at just one post.

Related↓

Elastic Stock Plunges Despite Strong Q2 Earnings Beat
11/21/2025 · 6:21 AM

Elastic Stock Plunges Despite Strong Q2 Earnings Beat

Elastic N.V. shares dropped 12% despite beating earnings expectations with $0.64 EPS and raising full-year guidance, as investors focus on widening losses.

/ Subscriber only
/ Read more

Feed↓

FDA Approves First SMA Drug That Targets Muscle Loss, Not Just Nerves
Featured/ 09/11/2026 · 5:55 PM

FDA Approves First SMA Drug That Targets Muscle Loss, Not Just Nerves

The FDA approved Scholar Rock’s Isembyld, the first SMA therapy aimed at muscle wasting in patients already on nerve-targeted treatment.

/ Subscriber only
AstraZeneca’s Etcamah Combination Falls Short of Statistical Significance in SERENA-4
Featured/ 09/11/2026 · 4:48 PM

AstraZeneca’s Etcamah Combination Falls Short of Statistical Significance in SERENA-4

The Phase III SERENA-4 trial did not meet its primary PFS endpoint in untreated advanced ER-positive, HER2-negative breast cancer, despite a numerical benefit.

/ Subscriber only
Citi Says AppLovin Is Positioned to Meet or Beat Q3 Guidance
09/11/2026 · 4:30 PM

Citi Says AppLovin Is Positioned to Meet or Beat Q3 Guidance

Citi added a 90-day upside view on AppLovin with a $600 target, calling Q3 concerns misguided.

/ Subscriber only
  • UP↑
  • Terms/Privacy
  • Sign up
  • Sign in
  • Discord
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Invest ↗
  • NOTRELOAD AI
DON'T FALL BEHIND. ©2025
Email address Subscribe